Jane I Grove

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7157611/publications.pdf

Version: 2024-02-01

36	1,851	361045	395343
papers	citations	20	33
		h-index	g-index

37	37	37	1982
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology, 1998, 27, 1695-1699.	3.6	205
2	Association of Liver Injury From Specific Drugs, or Groups ofÂDrugs, With Polymorphisms in HLA and Other Genes in aÂGenome-Wide Association Study. Gastroenterology, 2017, 152, 1078-1089.	0.6	174
3	A seven-gene operon essential for formate-dependent nitrite reduction to ammonia by enteric bacteria. Molecular Microbiology, 1994, 12, 153-163.	1.2	163
4	Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis. Gut Microbes, 2020, 11, 569-580.	4.3	125
5	Regulation and sequence of the structural gene for cytochrome C552from Escherichia coli: not a hexahaem but a 50kDa tetrahaem nitrite reductase. Molecular Microbiology, 1993, 9, 1255-1265.	1.2	113
6	NITROREDUCTASE: A PRODRUG-ACTIVATING ENZYME FOR CANCER GENE THERAPY. Clinical and Experimental Pharmacology and Physiology, 2004, 31, 811-816.	0.9	102
7	RecN protein and transcription factor DksA combine to promote faithful recombinational repair of DNA double-strand breaks. Molecular Microbiology, 2005, 57, 97-110.	1.2	100
8	Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics and Genomics, 1998, 8, 543-552.	5.7	99
9	The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. Pharmacogenetics and Genomics, 1998, 8, 335-342.	5.7	94
10	Tumour necrosis factor-a promoter polymorphisms in primary biliary cirrhosis. Journal of Hepatology, 1999, 30, 232-236.	1.8	79
11	C282Y mutation in HFE (haemochromatosis) gene and type 2 diabetes. Lancet, The, 1998, 351, 1933-1934.	6.3	68
12	Kinetic and Structural Characterisation of Escherichia coli Nitroreductase Mutants Showing Improved Efficacy for the Prodrug Substrate CB1954. Journal of Molecular Biology, 2007, 368, 481-492.	2.0	66
13	Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications. Journal of Hepatology, 2018, 69, 948-957.	1.8	62
14	Drugâ€Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. Clinical Pharmacology and Therapeutics, 2019, 106, 245-253.	2.3	58
15	Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. Cancer Research, 2003, 63, 5532-7.	0.4	53
16	Human leukocyte antigen genetic risk factors of drug-induced liver toxicology. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 395-409.	1.5	47
17	No evidence for involvement of the interleukin-10 â^'592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis. Journal of Hepatology, 1998, 28, 820-823.	1.8	34
18	Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: Effects of combining beneficial single mutations. Biochemical Pharmacology, 2010, 79, 102-111.	2.0	32

#	Article	IF	Citations
19	Genetic Risk Factors in Drugâ€Induced Liver Injury Due to Isoniazidâ€Containing Antituberculosis Drug Regimens. Clinical Pharmacology and Therapeutics, 2021, 109, 1125-1135.	2.3	31
20	Site-specific Relaxase Activity of a VirD2-like Protein Encoded within the tfs4 Genomic Island of Helicobacter pylori. Journal of Biological Chemistry, 2013, 288, 26385-26396.	1.6	21
21	DNA double strand break repair and crossing over mediated by RuvABC resolvase and RecG translocase. DNA Repair, 2008, 7, 1517-1530.	1.3	20
22	A role for the tfs3 ICE-encoded type IV secretion system in pro-inflammatory signalling by the Helicobacter pylori Ser/Thr kinase, CtkA. PLoS ONE, 2017, 12, e0182144.	1.1	20
23	Genome-Wide Association Studies in Drug-Induced Liver Injury: Step Change in Understanding the Pathogenesis. Seminars in Liver Disease, 2015, 35, 421-431.	1.8	18
24	A soluble RecN homologue provides means for biochemical and genetic analysis of DNA double-strand break repair in Escherichia coli. DNA Repair, 2009, 8, 1434-1443.	1.3	14
25	Cellular location and activity of Escherichia coli RecG proteins shed light on the function of its structurally unresolved C-terminus. Nucleic Acids Research, 2014, 42, 5702-5714.	6.5	13
26	Accurate nonâ€invasive diagnosis and staging of nonâ€alcoholic fatty liver disease using the urinary steroid metabolome. Alimentary Pharmacology and Therapeutics, 2020, 51, 1188-1197.	1.9	13
27	Chronic liver disease in homeless individuals and performance of nonâ€invasive liver fibrosis and injury markers: VALID study. Liver International, 2022, 42, 628-639.	1.9	7
28	The Evaluation and Use of a Food Frequency Questionnaire Among the Population in Trivandrum, South Kerala, India. Nutrients, 2020, 12, 383.	1.7	6
29	ÂMonozygotic twins with NASH cirrhosis: cumulative effect of multiple single nucleotide polymorphisms?. Annals of Hepatology, 2016, 15, 277-82.	0.6	6
30	Development of Food Group Tree-Based Analysis and Its Association with Non-Alcoholic Fatty Liver Disease (NAFLD) and Co-Morbidities in a South Indian Population: A Large Case-Control Study. Nutrients, 2022, 14, 2808.	1.7	3
31	Analysis of genotyping for predicting liver injury marker, procollagen <scp>III</scp> in persons at risk of nonâ€alcoholic fatty liver disease. Liver International, 2018, 38, 1832-1838.	1.9	2
32	Effects of an isoenergetic low Glycaemic Index (GI) diet on liver fat accumulation and gut microbiota composition in patients with non-alcoholic fatty liver disease (NAFLD): a study protocol of an efficacy mechanism evaluation. BMJ Open, 2021, 11, e045802.	0.8	2
33	Gut Microbial Profile Is Associated With Residential Settings and Not Nutritional Status in Adults in Karnataka, India. Frontiers in Nutrition, 2021, 8, 595756.	1.6	1
34	Tumour necrosis factor-Î± promoter polymorphisms in primary biliary cirrhosis. European Journal of Gastroenterology and Hepatology, 1999, 11, 466.	0.8	0
35	P040â€…Identification and functional characterisation of a rare MTTP variant underlying hereditary non-alcoholic fatty liver disease. , 2021, , .		0
36	O08â€…Dietary factors underlying non-alcoholic fatty liver disease (NAFLD) and its severity: a large, population-based, case-control study. , 2021, , .		0